Cannabis Law Report

AUGUST 17, 2021

Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 76

Pharmaceutical Clinical Trials Treatment Patients 76

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Consumers spent roughly $31.3 increase in annual sales.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

DECEMBER 20, 2021

Data To Support Regulatory Filings in the United States. Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., BERWYN, Pa.–(BUSINESS

Clinical Trials 40

Clinical Trials Chronic Pain Pharmaceutical Data 40

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood. Chief Scientific Officer. MyMD Pharmaceuticals, Inc.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Therapy 40

The Cannigma

JUNE 15, 2021

The first clinical research done on CBD as a potential treatment for epilepsy was in 1980, but the information gleaned didn’t make its way to the public eye until decades later. However, the scientific data on CBG is nowhere near as developed as what we have on CBD. Shutterstock). It’s everywhere. An anti-seizure wonder drug.

CBD 122

CBD Research and Development Epilepsy Extraction 122

Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

When it comes to using CBD for anxiety, most clinical trials involved using very highly concentrated CBD, and there are no known severe adverse effects of consuming “too much” CBD. Even doses higher than 1,000mg have been safely administered in testing, and CBD is considered safe for children for the treatment of epilepsy.

Treatment 111

Treatment Conditions CBD Clinical Trials 111

Cannabis Law Report

SEPTEMBER 22, 2021

Data indicates potential of drug candidate to deliver an extremely potent therapeutic benefit at a very low non-toxic dose. New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. We look forward to providing continuing updates as we advance this drug candidate in the clinic.”.

Pharmaceutical 40

Pharmaceutical Data CBD Clinical Trials 40

Veriheal

APRIL 11, 2022

We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds. This means that U.S.

Pharmaceutical 105

Pharmaceutical Research and Development DEA Clinical Trials 105

Veriheal

MARCH 23, 2023

The report states that the revision is an essential move for ensuring the legal use of cannabis-derived epilepsy drug Epidiolex , which is currently being reviewed as part of a series of clinical trials in Japan. Japan’s latest Cannabis Control Law revisions would apply to pharmaceutical-grade medicinal cannabis products.

Legalization 81

Legalization Marijuana Clinical Trials Seed-To-Sale 81

CannaTech

SEPTEMBER 16, 2018

But this gap restricts patient access to a medicine that can offer relief to a long list of conditions including chronic pain, seizures attributed to epilepsy, as well as mood disorders such as anxiety and depression. This knowledge gap isn’t surprising, as cannabis as a medicine is non-traditional in its very nature.

Education 66

Education Medicine Clinical Trials Patients 66

The Joint Blog

JANUARY 23, 2020

. “Medicinal cannabis has been reported to have potential efficacy in reducing pain, muscle spasticity, chemotherapy-induced nausea and vomiting, and intractable childhood epilepsy. Yet its potential application in the field of psychiatry is lesser known.”

Clinical Trials 52

Clinical Trials Marijuana Sleep Cannabinoids 52

Cannabis Law Report

JANUARY 10, 2022

This high share is attributable to the rising adoption of THCV for various applications such as epilepsy, arthritis, metabolic disorders, neurological disorders, and pain management. Rising clinical trials is thus anticipated to boost the adoption and penetration of rare cannabis derivatives in the forthcoming years.

Cannabinoids 40

Cannabinoids Clinical Trials Research and Development Supply Chain 40

Canna Care Docs

DECEMBER 16, 2020

The evidence of its effectiveness is clear, as clinical trials have shown a significant reduction in pain for patients suffering with neuropathic pain from multiple sclerosis, pain from rheumatoid arthritis, cancer pain, HIV or complex regional pain syndrome, headaches and menstrual pain, among other potential uses. Chronic pain.

Chronic Pain 52

Chronic Pain Marijuana Clinical Trials Epilepsy 52

Cannabis Law Report

DECEMBER 8, 2021

Charles River Laboratories, a renowned CRO engaged by Virpax to perform Food and Drug Administration (FDA) required pre-clinical studies, has completed a single dose pharmacokinetic study of dermal administration of Epoladerm in minipigs as part of the required Investigational New Drug Application (“IND”) enabling trials.

Clinical Trials 40

Clinical Trials Chronic Pain Pharmaceutical Topical 40

Cannabis Law Report

DECEMBER 7, 2021

This trend is also observed in the pediatric population, where MCs are authorized in children for refractory epilepsy, especially in Dravet syndrome and Lennox-Gastaut syndrome 2. A systematic review published in 2017 aimed to identify available data about the therapeutic effect of cannabinoids treatment in children and adolescents.

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

JUNE 7, 2022

While more data is needed to confirm all these, its effects on our physical bodies show promise so far. Did you know that CBD is approved to treat seizures caused by different types of epilepsy? This was when clinical trials found a significant reduction in seizures for people who took CBD. Alleviates Seizures.

Chronic Pain 52

Chronic Pain CBD Digestion Edibles 52

Cannabis Law Report

JANUARY 13, 2020

Advance the medical literature regarding Epidiolex through publications in top-tier medical journals and at major scientific and medical meetings, notably the American Academy of Neurology and American Epilepsy Society meetings. Execute NHIE clinical program utilizing an intravenous formulation of cannabidiol.

Pharmaceutical 51

Pharmaceutical Clinical Trials Research and Development Programs 51

Puff Puff Post

JANUARY 1, 2020

Sativex is a cannabinoid medication prescribed to cancer patients and individuals suffering from epilepsy and other muscle disorders. Nabiximol is a cannnabis derived drug that exited clinical trials in Spain. Consequentially, insurance companies need government approval to subsidise treatments.

Treatment 49

Treatment Clinical Trials Research and Development Cannabinoids 49

The Joint Blog

FEBRUARY 24, 2021

Numerous trials have been run using medical marijuana and CBD tinctures to treat or reduce the symptoms of Parkinson’s Disease. This is not the first medicinal trial of its kind. Cannabis and CBD oils have often been used to reduce the effects of epilepsy and several other neurological issues, so why not Parkinson’s?

Treatment 55

Treatment Clinical Trials Collective Patients 55

Cannabis Law Report

NOVEMBER 16, 2021

Believed to be the only IND application ever cleared by the FDA for a Phase 2 trial of a patented drug for delaying aging. Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 40

Pharmaceutical Clinical Trials Research and Development Therapy 40

Cannabis Law Report

OCTOBER 6, 2021

With the additional funding recently secured by Virpax and the strengthening of our balance sheet, we are continuing to advance our product candidates and to move them through preclinical studies and into human clinical trials,” said Anthony Mack, Chairman and Chief Executive Officer of Virpax Pharmaceuticals.

Research and Development 40

Research and Development Clinical Trials Pharmaceutical Chronic Pain 40

Cannabis Law Report

OCTOBER 26, 2021

MyMD plans to advance MYMD-1 in the clinic with two simultaneous Phase 2 trials beginning in the current quarter, one for delaying aging and prolonging healthy lifespan, and the second for COVID-19-associated depression and cytokine elevation. 1 Data published by Research and Markets, March 2018. Dr. Chapman Bio. 646) 421-9523.

Pharmaceutical 40

Pharmaceutical Clinical Trials Research and Development Therapy 40

Puff Puff Post

JANUARY 1, 2020

Sativex is a cannabinoid medication prescribed to cancer patients and individuals suffering from epilepsy and other muscle disorders. Nabiximol is a cannnabis derived drug that exited clinical trials in Spain. Consequentially, insurance companies need government approval to subsidise treatments.

Treatment 40

Treatment Clinical Trials Research and Development Cannabinoids 40

Puff Puff Post

DECEMBER 28, 2018

An official study is aimed to conclude in July of 2019, where we’ll see all the data which comes forth. Initially, he refused their requests due to insufficient data, however the evidence shown by a recent study done in Israel on CBD managing epilepsy was enough to sway him in the other direction.

Treatment 76

Treatment Oil CBD Therapy 76

Cannabis Law Report

JULY 12, 2019

The opening of London’s first such clinic follows the opening of Britain’s first medical cannabis clinic in Greater Manchester earlier in the year. Access is clearly in demand from Londoners as there is already a waiting list of 150 patients at the London clinic ahead of its opening.

Epilepsy 40

Epilepsy Medicine Clinical Trials Chronic Pain 40

The Cannigma

DECEMBER 22, 2021

Listen & Subscribe: Israel is world-renowned for the research and innovation that is taking place there, and unofficial data suggests that around 20% of the Israeli population uses cannabis. We have autism and epilepsy. Despite this, being in possession of a prescription is the only way that cannabis can be legally consumed.

Research and Development 83

Research and Development Oil Cannabis Clinical Trials 83

Cannabis Law Report

OCTOBER 1, 2021

Virpax recently acquired global rights to VRP324, a product candidate for the intranasal delivery of a pharmaceutical-grade Schedule V cannabidiol (CBD) for the management of epilepsy in children, a rare pediatric disease. For more information, please visit www.virpaxpharma.com. About Noble Capital Markets, Inc. About Channelchek.

Research and Development 40

Research and Development Pharmaceutical Clinical Trials Chronic Pain 40

Cannabis Law Report

NOVEMBER 15, 2021

Finally, we recently acquired the worldwide rights to VRP324, which is an intranasal pharmaceutical-grade cannabidiol product candidate for the management of epilepsy in children (rare pediatric disease) and adults. VRP324 represents our first CNS disorder product indication. On September 9, 2021, Jeffrey A. Forward-Looking Statement.

Pharmaceutical 40

Pharmaceutical Research and Development Clinical Trials Chronic Pain 40

Cannabis Law Report

NOVEMBER 10, 2021

Once the Envelta IND-enabling studies are submitted to the FDA, the data may be cross-referenced to our cancer pain and PTSD INDs. Envelta™ has demonstrated analgesic potential in animal models without developing opioid tolerance, withdrawal, respiratory depression, euphoria, or addiction associated with the use of morphine.

Research and Development 40

Research and Development Chronic Pain Pharmaceutical Clinical Trials 40

Cannabis Law Report

JUNE 1, 2021

Director of Medical Affairs and a Product Development Team lead at Greenwich Biosciences, where he played an important role in the complex, successful commercialization of the first cannabis-based product approved by the FDA to treat rare forms of epilepsy.

Research and Development 51

Research and Development Treatment Pharmaceutical Patients 51

Cannabis Law Report

NOVEMBER 24, 2021

At the same time, the outlook on cannabis research data is largely positive. Chronic pain or pain were the conditions most frequently mentioned in articles about cannabis, followed by epilepsy, cancer or cancer pain, and nausea and chemotherapy. Refractory paediatric epilepsy. Data collection. Palliative care indications.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

JANUARY 20, 2022

ELE-Psilo program expected to enter clinical trials in Q2 2022 and to target the pressing need for rapid-acting antidepressants compatible with existing healthcare infrastructure and insurance. Eleusis secured an Innovation Passport Designation for ELE-Psilo in adult treatment-resistant depression under the U.K.

Therapy 40

Therapy Research and Development Business Access 40

Veriheal

AUGUST 31, 2020

Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death. Essay: “Crowdsourcing User Experience Data for a Targeted Medical Cannabis Journey with Cannamunity” . School: Tufts University.

Research and Development 119

Research and Development Education Agriculture Patients 119

Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. What about other medical cannabis products? PDF Version.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

JULY 12, 2019

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. Lancet Neurol Dec 23 2015.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

Greencamp

AUGUST 16, 2018

The CBD cannabinoid is proven to be an exceptional seizure-controlling agent for epilepsy patients, and also shows great promise for treating Parkinson’s , Alzheimer’s and Multiple Sclerosis. Marijuana and Epilepsy: Here’s How Cannabis Stops Seizures (12 Studies). Exploring the available research on ALS and cannabinoids.

Strains 94

Strains Cannabinoids Research and Development Indica 94

The Joint Blog

JANUARY 12, 2020

“The growth is more rapid than I’ve seen for any product in 20 years in this business,” said Bill Bookout, president of the National Animal Supplement Council, an industry group whose member companies agree to testing and data-gathering requirements. There’s a gold rush going on now. That’s starting to change, however.

Pets 36

Pets CBD Clinical Trials Research and Development 36